Many of Europe’s nearly 2 million rheumatoid arthritis patients are still unable to access effective new biologic treatments, and whether they can do so or not is largely dependent on where they live, says a new study…
The largest differences in access are due to a global price for the drugs and large differences in wealth among the 30 nations, says the study.
Read More: http://www.pharmatimes.com/WorldNews/article.aspx?id=16729
